Polar Capital Biotech I Inc
SpecialistPricing frequency
Daily
Dealing cut off time
13:45
Type
OEIC
Yield
–
NAV
$63.71
Income frequency
Annually
Ongoing charge
1.1%
Latest actual NAV date
18-03-2026
ISIN
IE00B42Z4531
UCITS
Yes
This fund can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Before investing please read:
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/01/2026 | % of assets |
|---|---|
| Northern Trust Global US Dollar F | 9.11 |
| argenx SE | 5.03 |
| Arcutis Biotherapeutics Inc Ordinary Shares | 4.49 |
| UCB SA | 4.46 |
| Regeneron Pharmaceuticals Inc | 4.46 |
| Madrigal Pharmaceuticals Inc | 4.41 |
| Rhythm Pharmaceuticals Inc | 3.62 |
| Revolution Medicines Inc Ordinary Shares | 3.43 |
| AstraZeneca PLC | 3.30 |
| BridgeBio Pharma Inc | 3.28 |
Investment objective
The investment objective of the Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of biotechnology, diagnostics and life sciences tools companies.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.
Morningstar ratingTM
Morningstar sustainability ratingTM
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.